Alexandria Real Estate Equities

NYSE: ARE

Stock price

52.9 USD

(+0%) TODAY

Financial Performance

Share

5Y price score: (104)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: (12.5)%

DATE RANGE:

US$ Per
Share

By default your notes are visible only to you.

39.4

52-week range

88.2

52.9

Your model inputs

Required return / cost of capital
%
FCFF terminal growth rate
%

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

Help
FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

9.6 %

Dividend Yield TTM

6.6 %

Market cap $

$ 9,219

Price / Earnings TTM

Help
P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

(9.5)

Price / Book TTM

0.6

PEG TTM

Help
Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

(0.1)

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

(28.4) %

(62.3) %

(12.5) %

Free cash flow per share growth

(113) %

18.9 %

274.2 %

Earnings per share growth

110.3 %

(280.7) %

(617.8) %

Founded: 1,994

Employees: 552

Business Summary:Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® real estate investment trust, stands as the pioneering and most seasoned entity in the specialized domain of urban office properties. Since its inception in 1994, Alexandria has uniquely focused on the ownership, operation, and development of integrated campuses tailored for the life science, technology, and agtech sectors, strategically positioned within premier innovation ecosystems. By December 31, 2020, the company commanded a market capitalization of $31.9 billion and managed an extensive North American asset portfolio totaling 49.7 million square feet. This substantial base encompasses 31.9 million RSF of operational properties, 3.3 million RSF of premium Class A spaces currently under construction, 7.1 million RSF designated for near-to-mid-term development and refurbishment, and an additional 7.4 million SF earmarked for future projects. Alexandria has cultivated a significant footprint across vital innovation hubs such as Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle. Its established expertise lies in crafting superior Class A facilities within these urban campuses, fostering dynamic and collaborative environments. These spaces are instrumental in empowering innovative tenants to successfully attract and retain world-class professionals, thereby stimulating productivity, efficiency, creativity, and overall achievement. Furthermore, Alexandria extends its support to transformative life science, technology, and agtech companies through its dedicated venture capital platform. This distinct business model, coupled with rigorous underwriting practices, ensures a diverse and high-caliber tenant roster, ultimately driving elevated occupancy rates, extended lease durations, robust rental revenues, superior financial returns, and enhanced long-term asset appreciation.

Fair Value Reference Estimate

Latest Earnings Call Takeaways

2026 Q2 (Aug 4, 2026)

1) Leasing Performance and Tenant Dynamics - Alexandria Real Estate Equities (ARE) reported solid leasing volume of 1,039,000 square feet in Q2 2026, up 60% from the previous quarter and 9% year-over-year. - The company’s tenant base remains strong, with 75% of leasing activity coming from existing tenants. Notably, 40% of leasing volume was from the life science sector, while 30% came from advanced technology. - Public biotech leasing increased to 5.8% of total leasing volume, indicating a recovery in that segment. - Occupancy at the end of Q2 was 86.9%, down 80 basis points from the prior quarter, primarily due to lease expirations. The company expects occupancy to stabilize with 1.4 million square feet of leases commencing in November 2026.

2) Financial Results and Guidance - Funds from Operations (FFO) per share diluted as adjusted was $1.73 for Q2 2026, with guidance for the full year reaffirmed at $6.40, tightening the range to +/- $0.05. - Same-property net operating income (NOI) declined 10.6% year-over-year, but this was an improvement from the previous quarter's performance. - The company is targeting $2.9 billion in dispositions for 2026, with 46% already completed or pending, and another 38% in process.

3) Capital Management and Disposition Strategy - ARE has extended its $5 billion credit facility to 2032, enhancing liquidity. - The company is focused on reducing capital expenditures (CapEx) from a $1.75 billion construction pipeline, with 71% of projects currently leased. - Impairments of $222.5 million were recognized during the quarter, primarily related to land and properties originally intended for laboratory conversion.

4) Market Conditions and Operational Challenges - The life science real estate market remains challenging, with ongoing concerns about regulatory environments and market sentiment. However, there is a positive outlook for innovation and financing in the sector. - The company is closely monitoring interest rates and tenant health, noting that private venture funding has seen a resurgence. - Occupancy challenges are expected to persist with 1.4 million square feet of key lease expirations in 2027, which could lead to downtime of 12 to 24 months.

5) Outlook and Strategic Focus - Looking ahead, ARE projects 950,000 square feet of leasing volume for Q3 2026, with a focus on managing lease expirations and improving occupancy. - The company is evaluating its development projects and may pivot to advanced technology strategies if demand shifts. - The earnings call did not provide specific insights into the long-term impacts of potential impairments or the overall market recovery trajectory.

Bottom line: Alexandria Real Estate Equities is navigating a complex market with solid leasing performance and a strong tenant base. While facing challenges in occupancy and regulatory environments, the company remains focused on capital management and strategic dispositions, positioning itself for a potential recovery in the life science sector.

Annual Reports, Presentations And IR Contacts

Go to the website

Alexandria Real Estate Equities — Financial Overview, Stock Price, Market Cap

Alexandria Real Estate Equities is a company. Founded in 1994. As of August 26, 2026, the company's market capitalization is $9218830100 with a current stock price of $52.90.